



Welcome!

Mitch Coyne, Sr. VPGM Product and Service

6 March 2023

We Unite All Our Solutions and Offerings Under One Azenta Life Sciences Company




































Unrivaled Sample Exploration & Management Solutions





We offer enterprise-wide sample exploration and management solutions across the drug development pipeline.



Genomics & Analytical Services



Sample Sourcing



Storage, Automation & Logistics



Consumables & Instruments



Data & Informatics



Consultative Services

Unrivaled Sample Solutions to Accelerate Discovery, Development, and Delivery





RESEARCH & DISCOVERY



- Save time and improve precision
- Sample procurement
- Process efficiency improvements
- Informatics

PRE-CLINICAL & CLINICAL



- Quickly retrieve and move samples
- Maximize sample usage
- Maintenance of clinical grade standards
- Sample workflow data management

MANUFACTURING & DISTRIBUTION




- Compliant deployment of therapies
- Ensure proper storage conditions
- Sophisticated product tracking
- Leverage genomics for QA/QC

Azenta Life Sciences | Proprietary and confidential.

Well-Positioned in Key Global Life Science Market >3500 employees







Our History and Journey Highlights

Building a life sciences company for over 20 years





2011 - 2012 RTS Nexus



Matrical BioCision (22%)

2013 - 2014



FluidX BioStorage Technolgies

2015 - 2016



BioCision PBMMI FreezerPro 4titude Ltd. BioSpeciMan


2017 - 2018



2019 GENEWIZ



2020RURO
Trans-Hit
Biomarkers




Azenta Life Sciences Abeyance

2021



Barkey B Medical Systems

2022



2022 Was an Eventful Year

Barkey Acquisition July 1

"Barkey will add innovative products and capabilities that extend our extensive cold chain of condition portfolio of products and services, while also expanding our customer reach in the fast-growing CGT space, with more than 100 CGT customers to date. The controlled rate thawing of cryopreserved products to maximize reproducibility and viability of the sample is a natural extension of our advanced cryogenic offerings."



Steve Schwartz,
President and CEO of Azenta





B Medical Acquisition Oct 3

"We are excited to add B Medical into our growing portfolio of offerings. B Medical has done an outstanding job carving out a strong market position in the vaccine cold chain, and we see a breadth of opportunities to drive even further value from the portfolio by leveraging the Azenta platform."



Steve Schwartz,
President and CEO of Azenta








C&I Business Overview



SALES CHANNEL



A strong distributor relationship is a key component of our go-to-market strategy



You are an important part of our sales team! You are a face of our company!

We want to be a partner, not a vendor!
We need your market feedback!
Help us to understand how we can be of better support!

Let us share product news & align on strategies!

Azenta Life Sciences | Proprietary and confidential.

C&I Business Overview




2019 - 2023 REVENUE WALK



PRODUCT MIX

REGIONAL SALES DISTRIBUTION





C&I products were key components in Covid testing workflows. Taking Covid business out, C&I is showing a 2019-2023 CAGR of 13%.

New capacities will allow us to go aggressively after any large opportunity!

C&I Market Overview







C&I market is divided into two main sections with a TAM of \$300M each





Partnering for Growth Stronger Together!!





Thank you!

